Corbus Pharmaceuticals Holdings, INC. (CRBP) — SEC Filings

Overview

Corbus Pharmaceuticals Holdings, INC. (CRBP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B3 filed on Mar 25, 2026: Corbus Pharmaceuticals Holdings, Inc. filed a 424B3 prospectus on March 25, 2026, related to their registration statement 333-294217. This filing is a standard update to a previous registration, likely for the sale of securities, and indicates the company is maintaining its ability to raise capital.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 46 neutral. The dominant filing sentiment for Corbus Pharmaceuticals Holdings, INC. is neutral.

Filing Type Overview

Corbus Pharmaceuticals Holdings, INC. (CRBP) has filed 22 8-K, 1 424B3, 5 10-Q, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 7 SC 13G, 1 10-K/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 8-K Filing — 8-K · Apr 7, 2026
• Corbus Pharma Files 424B3 Prospectus, Maintains Capital Raising Option — 424B3 · Mar 25, 2026
  Corbus Pharmaceuticals Holdings, Inc. filed a 424B3 prospectus on March 25, 2026, related to their registration statement 333-294217. This filing is a standard
• Corbus Pharma Reports Director/Officer Changes & Compensation — 8-K · Dec 18, 2025 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on December 18, 2025, reporting on events as of December 12, 2025. The filing covers the departure of directo
• 8-K Filing — 8-K · Dec 11, 2025
• Corbus Pharmaceuticals Files 8-K on Financials — 8-K · Nov 12, 2025 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on November 12, 2025, reporting on its results of operations and financial condition. The filing also include
• 8-K Filing — 8-K · Nov 3, 2025
• Corbus Pharmaceuticals Files 8-K — 8-K · Oct 30, 2025 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on October 30, 2025, to report on other events. The filing does not contain specific details about the nature
• Corbus Pharmaceuticals Files 8-K — 8-K · Oct 20, 2025 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on October 20, 2025, reporting events as of October 18, 2025. The filing includes information related to Regu
• Corbus Pharmaceuticals Files 8-K — 8-K · Sep 16, 2025 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on September 16, 2025, reporting on various events. The filing includes information related to Regulation FD
• Corbus's Net Loss Widens to $10.2M Amid R&D Shifts — 10-Q · Aug 5, 2025 Risk: high
  Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $10.2 million for the three months ended June 30, 2025, a significant increase from the $7.8 millio
• Corbus Pharmaceuticals Files 8-K on Shareholder Vote & Other Events — 8-K · May 19, 2025 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on May 19, 2025, reporting on matters submitted to a vote of security holders and other events that occurred
• Corbus Pharma Files 10-Q for Q1 2025 — 10-Q · May 6, 2025 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including assets and liabil
• Corbus Pharma Files 2025 DEF 14A — DEF 14A · Apr 1, 2025 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed a DEF 14A on April 1, 2025, for the fiscal year ending December 31, 2025. The filing details executive compensation
• Corbus Pharma Reports Director/Officer Changes — 8-K · Mar 21, 2025 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on March 21, 2025, reporting changes effective March 20, 2025. The filing covers the departure of directors o
• Corbus Pharma Reports Director/Officer Changes & Financials — 8-K · Mar 18, 2025 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on March 18, 2025, reporting on events as of March 13, 2025. The filing covers the departure of directors or
• 10-K Filing — 10-K · Mar 11, 2025
• Corbus Pharmaceuticals Files 8-K — 8-K · Feb 14, 2025 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on February 14, 2025, reporting its status as a publicly traded company. The filing confirms its principal ex
• Corbus Pharmaceuticals Files 8-K — 8-K · Dec 3, 2024 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on December 3, 2024, to report on various events. The filing includes information related to Regulation FD di
• Corbus Pharmaceuticals Files 8-K — 8-K · Nov 15, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on November 15, 2024, reporting an "Other Event." The filing does not contain specific details about the even
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Corbus Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and business opera
• Corbus Pharmaceuticals Files 8-K — 8-K · Nov 4, 2024 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on November 4, 2024, reporting its corporate information. The company is incorporated in Delaware and its pri
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G Filing — SC 13G · Oct 22, 2024
• SC 13G/A Filing — SC 13G/A · Oct 15, 2024
• SC 13G Filing — SC 13G · Oct 11, 2024
• KKR to Acquire Corbus Pharmaceuticals for $335M — 8-K · Sep 3, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. announced on August 29, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of KKR & Co.
• Corbus Pharma Reports Director/Officer Changes & Compensation — 8-K · Aug 20, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on August 20, 2024, reporting events as of August 15, 2024. The filing primarily concerns the departure of di
• Corbus Pharma Files 10-Q, Details Loan and Warrant Activity — 10-Q · Aug 6, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition, including details on
• KKR to Acquire Corbus Pharmaceuticals — 8-K · Jun 17, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. announced on June 14, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of KKR & Co. In
• 8-K Filing — 8-K · Jun 3, 2024
• Corbus Pharma Reports Director/Officer Changes & Shareholder Votes — 8-K · May 20, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on May 20, 2024, reporting events as of May 16, 2024. The filing indicates changes related to the departure o
• KKR to Acquire Corbus Pharmaceuticals for $3.00/Share — 8-K · May 9, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. announced on May 9, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of KKR & Co. Inc.
• Corbus Pharmaceuticals Holdings, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Corbus Pharmaceuticals Holdings, Inc. filed a 10-Q rep
• Corbus Pharma Reports Director Changes & Financials — 8-K · Apr 10, 2024 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on April 10, 2024, reporting on the departure of directors, election of new directors, appointment of officer
• Corbus Pharmaceuticals Holdings, Inc. DEF 14A Filing — DEF 14A · Apr 2, 2024 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed a Proxy Statement (DEF 14A) with the SEC on April 2, 2024. Corbus Pharmaceuticals Holdings, Inc. filed a DEF
• Corbus Pharmaceuticals Holdings, Inc. Files 10-K/A Amendment — 10-K/A · Mar 20, 2024 Risk: low
  Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed a Amended Annual Report (10-K/A) with the SEC on March 20, 2024. Corbus Pharmaceuticals Holdings, Inc. filed
• SC 13G/A Filing — SC 13G/A · Mar 18, 2024
• Corbus Pharmaceuticals Holdings, Inc. Files 2023 Annual Report (10-K) — 10-K · Mar 12, 2024 Risk: medium
  Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed a Annual Report (10-K) with the SEC on March 12, 2024. Corbus Pharmaceuticals Holdings, Inc. filed its 2023 1
• SC 13G Filing — SC 13G · Feb 28, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• RA Capital Discloses Significant Stake in Corbus Pharma (CRBP) — SC 13G · Feb 12, 2024 Risk: low
  RA Capital Management, L.P., a prominent investment firm, filed an SC 13G on February 12, 2024, disclosing its ownership in Corbus Pharmaceuticals Holdings, Inc

Related Companies

KKR

Frequently Asked Questions